Wolff Wiese Magana’s Lineage Cell Therapeutics LCTX Stock Holding History

Wolff Wiese Magana’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31K	Hold	1,000	–	–	﹤0.01%	884
2026 Q1	$1.58K	Hold	1,000	–	–	﹤0.01%	812
2025 Q4	$1.67K	Hold	1,000	–	–	﹤0.01%	772
2025 Q3	$1.69K	Hold	1,000	–	–	﹤0.01%	786
2025 Q2	$908	Hold	1,000	–	–	﹤0.01%	853
2025 Q1	$452	Buy	+1,000	New	+$587	﹤0.01%	925

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

RCWM

Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TCOT

Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

BWCS

Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Wolff Wiese Magana's LCTX Position: Q2 2026 in Review

Wolff Wiese Magana held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 1,000 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

Wolff Wiese Magana first reported a position in LCTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.69K in Q3 2025. 32 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Wolff Wiese Magana held 1,000 shares of Lineage Cell Therapeutics worth $1.31K as of Q2 2026.
Wolff Wiese Magana left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Wolff Wiese Magana's portfolio in Q2 2026, its #884 holding.
Wolff Wiese Magana first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 6 quarters since.
Wolff Wiese Magana's Lineage Cell Therapeutics position peaked at $1.69K in Q3 2025.
32 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.